The Immunosuppressive Ligands PD-L1 and CD200 are Linked in AML T-cell Immunosuppression: Identification of a New Immunotherapeutic Synapse

Coles, Steven ORCID: https://orcid.org/0000-0002-1109-6971, Gilmour, M.N., Reed, R., Knapper, S., Burnett, A.K., Man, S., Tonks, A. and Darley, R.L. (2015) The Immunosuppressive Ligands PD-L1 and CD200 are Linked in AML T-cell Immunosuppression: Identification of a New Immunotherapeutic Synapse. Leukemia, 29 (9). pp. 1952-1954. ISSN Print: 0887-6924 Online: 1476-5551

	Text (Word document) 14-LEU-1317 letter.docx - Accepted Version Restricted to Repository staff only Download (49kB) | Request a copy
Preview	Text (PDF) The immunosuppressive ligands PD-L1 and CD200 are linked in AML T cell immunosuppression.pdf - Accepted Version Download (91kB) | Preview

Abstract

Long-term remission in acute myeloid leukemia (AML) is generally not durable only being achieved in <50% of patients. Consequently there is a need to establish new treatments to prevent relapse. A promising approach is to augment the anti-tumor immune response in these patients; however, it is well established that overexpression of immunosuppressive molecules such as CD200 on the surface of AML cells directly suppresses the antitumor response. Nevertheless, blocking CD200:CD200R, only partially restores T-cell activity, suggesting that alternative immunosuppressive mechanisms need to be explored if the antitumor response in AML is to be optimally exploited.

Actions (login required)

View Item